UBS Group
CODX

UBS Group’s Co-Diagnostics CODX Stock Holding History

UBS Group’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-333
Closed -$194K – 8034
2020
Q2 		$194K Buy
+333
New +$152K ﹤0.01% 4814

Other funds holding CODX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAG
Private Advisory Group Redmond, Washington $1.85B AUM 50.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group's CODX Position: Q2 2026 in Review

UBS Group increased its Co-Diagnostics (CODX) stake by 118% in Q2 2026, buying an estimated $26.8K and bringing the position to 16,091 shares worth $49.9K. The position accounts for ﹤0.01% of the portfolio, ranked #7560.

UBS Group first reported a position in CODX in Q4 2017 and has held it in 33 quarters since. The position peaked at $440K in Q2 2020. 24 funds tracked by Wall St. Rank hold CODX as of Q2 2026.

  • UBS Group held 16,091 shares of Co-Diagnostics worth $49.9K as of Q2 2026.
  • UBS Group bought 8,723 Co-Diagnostics shares in Q2 2026, an estimated $26.8K.
  • Co-Diagnostics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7560 holding.
  • UBS Group first reported a position in Co-Diagnostics in Q4 2017 and has held it in 33 quarters since.
  • UBS Group's Co-Diagnostics position peaked at $440K in Q2 2020.
  • 24 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.